

# **MO HealthNet Pharmacy**

## **SmartPA – Pharmacy Prior Authorization**

**Joshua Moore, PharmD**  
**Director of Pharmacy**  
**February 13, 2020**

# MHD Pharmacy Goal

**Enable and support the best  
treatment for MO HealthNet  
Participants in a fiscally  
responsible and sustainable way**



# Pharmacy Policy Management Process

**What does evidence say is best practice?**


**What is everyone else doing?**

**What is the provider experience?**

**What does our data show?**

**What does the data mean?**

**What is the appropriate level of 3<sup>rd</sup> Party influence?**



# Drug Prior Authorization Process

## **Pipeline review**

- MHD reviews the pharmacy pipeline for new agents which are expected to be approved in the next 12 months


## **New medication is approved by FDA**

- This includes new molecule or dosage form

## **Medication reported to First Databank**

- Within 1 week the medication is placed on new drug review

## **MHD meets with team of clinicians to develop initial criteria**

- Initial criteria is used until the medication can be reviewed by advisory boards
- 

# Drug Prior Authorization Process

**MHD creates proposal documents for advisory committee**

## **Rare Disease Medications**

- If medication impacts <200,000 participants will be reviewed by Rare Disease Advisory Committee

## **Prior Authorization Committee**

- Public meeting to review PA criteria

## **Drug Utilization Review Board**

- Public meeting to review PA criteria and Drug Utilization information

**MHD implements criteria in the SmartPA System**



# MO HealthNet Criteria

## Preferred Drug List (PDL) Edits

- Contain preferred and non-preferred agents and may have clinical criteria

## Clinical Edits

- Contain clinical criteria, dosage limitations, and other criteria as needed

## Fiscal Edits


- Criteria is limited to dose unit optimization and refill too soon limits

## MO HealthNet Criteria

- Posted on MO HealthNet's website
- Reviewed by DPAC and DUR Committee on annual basis at the quarterly meetings
- Also may be reviewed by Rare Disease Advisory Committee if disease impacts <200,000 persons in United States

# SmartPA Rules Engine

- 6 million claims evaluated by SmartPA
- 587k claims denied at Point of Sale (10%)
- 85k claims result in call to Pharmacy HD (14.5% of denied claims)
- 18k prior authorization requests denied (21% of requests, 0.3% of total claims submitted)
- Statistics for SFY19



# Benefits of SmartPA

**Transparent automated application of uniform standards**

**Real time authorization**

- Call center is able to enter overrides in real time

**Allows for high PDL Compliance**

- 96% Compliant to PDL

**Allows for clinical decisions to be embedded in the Point of Sale Transaction**

- Typically review up to 3 years of patient specific history when making decisions

**Interventions are able to shift utilization**

**Coming Fall 2020 – diagnosis code on pharmacy claims**




# Opioids & Benzodiazepines

## **Opioid utilization decreased by over 50% in 2 years**

- 508 million MME in calendar year 2017
- 252 million MME in calendar year 2019

## **Benzodiazepine utilization decreased by 19% after edit implemented**

- 1.2 million units dispensed in July 2019
  - Implemented mid-August 2019
  - 1.0 million units dispensed in October 2019
- 

**Questions?**

The slide features a white background with a light gray dot grid pattern. At the bottom, there are two overlapping decorative shapes: a large orange triangle pointing to the right, and a blue shape that follows the bottom edge of the orange one.